Transaction DateRecipientSharesTypePriceValue
17th December 2020David S. Grayzel1,700,000Open or private sale$18.10$30,770,000.00
17th December 2020Venture Fund Ix, L.P. Atlas1,700,000Open or private sale$18.10$30,770,000.00
25th November 2020Jessica Fees227Exercise of derivative$4.14$938.87
25th November 2020Jessica Fees173Exercise of derivative$4.27$738.71
25th November 2020Jessica Fees982Exercise of derivative$5.41$5,314.58
25th November 2020Jessica Fees1Exercise of derivative$4.27$4.27
28th October 2020Jessica Fees122Exercise of derivative$4.27$520.94
28th October 2020Jessica Fees4,773Exercise of derivative$4.14$19,741.13
14th October 2020Robert W. Ross4,000Open or private sale$10.05$40,200.00
14th September 2020Enterprise Associates 14, L.P. New2,000,000Other acquisition or disposition$0.00
Surface Oncology
Surface Oncology logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The company focuses on biological pathways critical to the immunosuppressive tumor microenvironment.

Ticker: SURF
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1718108
Employees: 49
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $93 M (99%)
Assets, Current: $118 M (8%)
Property, Plant and Equipment, Net: $6 M (-11%)
Other Assets, Noncurrent: $64 Th (128%)
Assets: $155 M (17%)
Accounts Payable, Current: $530 Th (-84%)
Liabilities, Current: $11 M (-45%)
Liabilities: $57 M (-24%)
Common Stock, Value, Issued: $4 Th (33%)
Common Stock, Shares, Issued: $39 M (40%)
Additional Paid in Capital, Common Stock: $211 M (18%)
Retained Earnings (Accumulated Deficit): $114 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $54 Th (-47%)
Stockholders' Equity (Parent): $98 M (0%)
Liabilities and Equity: $155 M (17%)
Revenue: $0 (-100%)
Research and Development: $10 M (-54%)
General and Administrative Expenses: $5 M (-48%)
Operating Income/Loss: $15 M (82%)
EPS (basic): $0.44 (0%)
EPS (diluted): $0.44 (0%)